Why Markets Are At Record Highs Despite Global Tariffs
Stock markets continued to record highs despite the looming August 1 hike in tariffs. This is for good reason. After April 3’s Liberation tariff announcement, the White House almost immediately paused the proposed tariff rates.When the trade negotiation deadline of July 9 passed, nothing happened, either. In response, the S&P 500 (IVV) and Nasdaq (QQQ) closed at a record high. Alphabet (GOOG) gained 2.7%, ahead of its earnings report for Wednesday.CEO Elon Musk’s involvement at DOGE is now a distant memory. Global sales of Tesla (TSLA) vehicles plunged, especially in Europe. Profit margins will shrink, yet TSLA stock performed well.Big technology, known as the magnificent seven, will propel the S&P 500’s earnings per share growth. According to LEG I/B/E/S, the EPS growth in Q2 is 6.7%.In today’s trading session, expect trading volume to exceed the average. Yesterday, trading volume on U.S. exchanges saw 19.7 billion shares traded. The average volume is 17.7 billion shares over 20 sessions.Watch for mining stocks like Cleveland Cliffs (CLF) and Freeport-McMoRan (FCX) to continue their uptrend. Conversely, speculations like Opendoor (OPEN) risks falling sharply. Opendoor traded as high as around $5.00 on Monday, compared to a 52-week low of $0.51. Shorts hold a 21.42% short float against the stock.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


